The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BSH 2019 | Effectiveness of hydroxyurea in pediatric SCD in the real world

Name: Effectiveness of hydroxyurea in pediatric SCD in the real world
Uploaded: 2019-04-02T17:43:45.000Z
Duration: 2 min 32 s
Description: Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. She discusses the effectiveness of hydroxyurea in children with sickle cell disease (SCD) via analysis of dose-response metrics in a large birth cohort in a tertiary SCD center.

Subarna Chakravorty • 2 Apr 2019

BSH 2019

Non-Malignant Sickle Cell Disease Hydroxyurea

Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. She discusses the effectiveness of hydroxyurea in children with sickle cell disease (SCD) via analysis of dose-response metrics in a large birth cohort in a tertiary SCD center.